This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Momenta Pharmaceuticals' CEO To Present At Morgan Stanley Healthcare Conference (Transcript)

Momenta Pharmaceuticals Inc. (MNTA)

Morgan Stanley Healthcare Conference Call

September 11, 2012, 02:30 pm ET

Executives

Craig Wheeler - President and CEO

Analysts

Dave Friedman - Morgan Stanley

Presentation

Operator

Dave Friedman - Morgan Stanley

Hello, I think we will get started here and thanks everyone for joining us. Dave Friedman, one of the biotech analyst here and in terms of disclosures, you can find personnel and research at Morgan Stanley disclosures on morganstanley.com/researchdisclosures. So more exciting things, I've got Craig Wheeler here, CEO and President of Momenta Pharmaceuticals and we're very happy to have you here and the team and maybe if we can start if you can just give, you know, one or two minute overview of the company and you guys have a very unique approach to the drug development world and so maybe a quick intro and then we’ll just jump right in.

Craig Wheeler

Sure. I would be happy to. And for those of you that follow the company long time, you know, it's really a challenge to give a short intro on the complexity of our company in two minutes, but I'll give you just a quick profile of who Momenta is and we're a company that was found and based on really unraveling complexity. I think that’s a simplest way to put it where we look at complex problems like biologics, like heparins and try to understand in much more detail the structure, the manufacturing and the biology of this.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,122.43 +70.70 0.41%
S&P 500 1,984.72 +11.09 0.56%
NASDAQ 4,460.6490 +35.9450 0.81%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs